BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 18043900)

  • 1. No association between BRCA mutations and sex ratio in offspring of Pakistani BRCA mutation carriers.
    Rashid MU; Torres D; Zaidi A; Rasheed F; Sultan F; Shakoori AR; Amin A; Hamann U
    Breast Cancer Res Treat; 2008 Jan; 107(1):155-6. PubMed ID: 18043900
    [No Abstract]   [Full Text] [Related]  

  • 2. Sex ratio distortion in offspring of families with BRCA1 or BRCA2 mutant alleles: an ascertainment bias phenomenon?
    Balmaña J; Díez O; Campos B; Majewski M; Sanz J; Alonso C; Baiget M; Garber JE
    Breast Cancer Res Treat; 2005 Aug; 92(3):273-7. PubMed ID: 16155798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical management of BRCA1 and BRCA2 mutation carriers.
    Domchek SM; Armstrong K; Weber BL
    Nat Clin Pract Oncol; 2006 Jan; 3(1):2-3. PubMed ID: 16407858
    [No Abstract]   [Full Text] [Related]  

  • 4. RNA analysis of eight BRCA1 and BRCA2 unclassified variants identified in breast/ovarian cancer families from Spain.
    Campos B; Díez O; Domènech M; Baena M; Balmaña J; Sanz J; Ramírez A; Alonso C; Baiget M
    Hum Mutat; 2003 Oct; 22(4):337. PubMed ID: 12955719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2.
    Kauff ND; Barakat RR
    J Clin Oncol; 2007 Jul; 25(20):2921-7. PubMed ID: 17617523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA-related ovarian carcinoma.
    Rubin SC
    Cancer; 2003 May; 97(9):2127-9. PubMed ID: 12712461
    [No Abstract]   [Full Text] [Related]  

  • 7. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High frequency of BRCA1/2 germline mutations in consecutive ovarian cancer patients in Poland.
    Brozek I; Ochman K; Debniak J; Morzuch L; Ratajska M; Stepnowska M; Stukan M; Emerich J; Limon J
    Gynecol Oncol; 2008 Feb; 108(2):433-7. PubMed ID: 17997147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No association of miscarriage and BRCA carrier status in Pakistani breast/ovarian cancer patients with a history of parental consanguinity.
    Rashid MU; Torres D; Rasheed F; Sultan F; Shakoori AR; Amin A; Schlaefer K; Hamann U
    Breast Cancer Res Treat; 2009 Jul; 116(1):211-3. PubMed ID: 18574689
    [No Abstract]   [Full Text] [Related]  

  • 10. BRCA1 and BRCA2 germline mutations in Korean breast cancer patients at high risk of carrying mutations.
    Ahn SH; Son BH; Yoon KS; Noh DY; Han W; Kim SW; Lee ES; Park HL; Hong YJ; Choi JJ; Moon SY; Kim MJ; Kim KH; Kwak BS; Cho DY
    Cancer Lett; 2007 Jan; 245(1-2):90-5. PubMed ID: 16455195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PARP inhibitors: will the new class of drugs match the hype?
    Tuma RS
    J Natl Cancer Inst; 2009 Sep; 101(18):1230-2. PubMed ID: 19738163
    [No Abstract]   [Full Text] [Related]  

  • 12. Androgen receptor expression in breast cancer patients tested for BRCA1 and BRCA2 mutations.
    Pristauz G; Petru E; Stacher E; Geigl JB; Schwarzbraun T; Tsybrovskyy O; Winter R; Moinfar F
    Histopathology; 2010 Dec; 57(6):877-84. PubMed ID: 21166701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenotypic expression of double heterozygosity for BRCA1 and BRCA2 germline mutations.
    Leegte B; van der Hout AH; Deffenbaugh AM; Bakker MK; Mulder IM; ten Berge A; Leenders EP; Wesseling J; de Hullu J; Hoogerbrugge N; Ligtenberg MJ; Ardern-Jones A; Bancroft E; Salmon A; Barwell J; Eeles R; Oosterwijk JC
    J Med Genet; 2005 Mar; 42(3):e20. PubMed ID: 15744030
    [No Abstract]   [Full Text] [Related]  

  • 14. Cancer. Complicated supercomplexes.
    Livingston DM
    Science; 2009 May; 324(5927):602-3. PubMed ID: 19407191
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of germ-line genetic variation on breast cancer survival in a population-based study.
    Goode EL; Dunning AM; Kuschel B; Healey CS; Day NE; Ponder BA; Easton DF; Pharoah PP
    Cancer Res; 2002 Jun; 62(11):3052-7. PubMed ID: 12036913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. G1738R is a BRCA1 founder mutation in Greek breast/ovarian cancer patients: evaluation of its pathogenicity and inferences on its genealogical history.
    Anagnostopoulos T; Pertesi M; Konstantopoulou I; Armaou S; Kamakari S; Nasioulas G; Athanasiou A; Dobrovic A; Young MA; Goldgar D; Fountzilas G; Yannoukakos D
    Breast Cancer Res Treat; 2008 Jul; 110(2):377-85. PubMed ID: 17902052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
    Mote PA; Leary JA; Avery KA; Sandelin K; Chenevix-Trench G; Kirk JA; Clarke CL;
    Genes Chromosomes Cancer; 2004 Mar; 39(3):236-48. PubMed ID: 14732925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of nuclear BRCA1 protein staining in normal tissue cells derived from BRCA1 and BRCA2 mutation carriers.
    De Brakeleer S; Bogdani M; De Grève J; Decock J; Sermijn E; Bonduelle M; Goelen G; Teugels E
    Mutat Res; 2007 Jun; 619(1-2):104-12. PubMed ID: 17445839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is It time to stratify for BRCA mutation status in therapeutic trials in ovarian cancer?
    Kauff ND
    J Clin Oncol; 2008 Jan; 26(1):9-10. PubMed ID: 18165631
    [No Abstract]   [Full Text] [Related]  

  • 20. Structure-based assessment of BRCA1 and BRCA2 mutations in a small Spanish population.
    Salgado J; Zabalegui N; García-Amigot F; Gil MC; González MS; García-Foncillas J
    Oncol Rep; 2005 Jul; 14(1):85-8. PubMed ID: 15944772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.